stockrow
Monday 9 November 2026
Export MOLN’s income statement to Excel — free account
Molecular Partners AG Sponsored ADR
MOLNMolecular Partners AG Sponsored ADR’s revenue for fiscal 2024 (year ended December 2024) was $5.6 million, down 28.0% from fiscal 2023.
- Revenue
- −98.9%
- EPS
- +8.27%
- Free cash flow
- +11.1%
Quarter to September 2026, against a year earlier
3.22
0.03
−0.92%
Follow MOLN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 23 | 20 | 11 | 21 | 10 | 11 | 199 | 8 | 6 | — | 6 | (15.9%) | — | 50 | — | — | |
| Gross margin, % | 0.00 | 94.28 | 0.00 | 0.00 | (500.12) | (471.23) | 73.23 | (593.15) | (877.95) | 0.00 | 0.00 | 0.0 pt | ||||||
| EBT | (18) | (26) | (38) | (37) | (67) | (70) | 123 | (69) | (61) | (74) | (65) | +16.9% | ||||||
| EBT margin, % | (80.78) | (127.05) | (357.66) | (177.95) | (671.82) | (653.91) | 62.16 | (880.71) | (1,087.35) | 0.00 | 0.00 | +80.8 pt | ||||||
| Net income | (18) | — | (38) | (37) | (67) | (70) | 123 | (69) | (61) | (74) | (60) | +16.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 1.11 | 0.00 | 0.50 | 0.98 | 0.40 | 0.34 | 6.12 | 0.24 | 0.17 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.89) | — | (1.79) | (1.74) | (2.68) | (2.25) | 3.80 | (2.10) | (1.81) | (1.99) | (1.68) | +9.3% | ||||||
| Cash flow | (1.68) | 0.00 | (2.01) | 0.01 | (1.24) | (3.21) | 3.83 | (2.01) | (1.98) | (1.66) | (1.45) | (0.2%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (0.07) | (0.05) | (0.05) | (0.03) | (0.02) | (0.02) | (0.01) | n/m | ||||||
| Free cash flow | (1.68) | 0.00 | (2.01) | 0.01 | (1.31) | (3.26) | 3.78 | (2.03) | (2.00) | (1.68) | (1.45) | 0.0% | ||||||
| Book value | 6.52 | 0.00 | 4.42 | 2.61 | 4.57 | 3.79 | 7.59 | 6.00 | 4.73 | 2.60 | 1.63 | (9.7%) | ||||||
| Shares, m | 20 | — | 21 | 21 | 25 | 31 | 32 | 33 | 34 | 37 | 38 | +6.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59 | 0.00 | 0.00 | — | 0.00 | 0.2 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.15 | 1.13 | 17.43 | 28.64 | — | 21.86 | 11.7 | ||||||
| P/B | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.25 | 0.91 | 0.70 | 1.00 | — | 1.98 | 3.9 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.45 | (0.19) | (9.12) | (1.43) | — | 9.32 | 3.7 | ||||||
| EV/FCF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3.02) | (0.33) | 1.07 | 0.12 | — | (0.94) | (0.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (34) | (40) | (43) | 0 | (31) | (100) | 124 | (66) | (67) | (62) | (56) | +6.7% | |||||
| Capex | (1) | (1) | (1) | (2) | (2) | (1) | (1) | (1) | (1) | (1) | 0 | (2.4%) | ||||||
| Free cash flow | (34) | (40) | (43) | 0 | (33) | (101) | 123 | (67) | (68) | (63) | (56) | +6.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 163 | 131 | 119 | 74 | 128 | 128 | 249 | 198 | 163 | 104 | 63 | (4.9%) | |||||
| Net debt | (177) | (144) | (101) | (95) | (185) | (145) | (261) | (208) | (170) | (112) | (71) | (4.9%) | ||||||
| Shareholders’ equity | 133 | 119 | 94 | 56 | 114 | 117 | 246 | 197 | 161 | 97 | 62 | (3.5%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (11.13) | (28.75) | (22.31) | (28.07) | (43.44) | (35.88) | 53.26 | (27.85) | (30.62) | (49.07) | (58.83) | (37.9) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (14.47) | (20.57) | (35.54) | (50.08) | (78.68) | (60.23) | 67.89 | (31.17) | (34.35) | (57.72) | (71.08) | (43.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 152 | 163 | 175 | 168 | 158 | 134 | — | (2.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 | 1.14 | 0.05 | 0.04 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Dec 2024 · fundamentals updated 2 Nov 2026
Molecular Partners AG Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| CMPX Compass Therapeutics, Inc. | $136.7M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $136.1M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $133.8M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MENS Jyong Biotech Ltd. | $133.6M | — | — | — | — | — | — | — | Compare |
| PDSB PDS Biotechnology Corporation | $129.2M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $119.2M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +11.07% (above 0%: growing) | 0.00% | 0.00% | |
| CHRS Coherus Oncology, Inc. | $119.0M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| Median of peers | $134.9M | — | — | +40.05% | — | −28.10% | 100.00% | 0.00% |